Portola Pharmaceuticals Inc (NASDAQ:PTLA) has received an average recommendation of “Hold” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $51.40.

A number of brokerages recently issued reports on PTLA. BidaskClub raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 24th. ValuEngine lowered Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Oppenheimer set a $80.00 price target on Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 5th. Zacks Investment Research raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 4th. Finally, Credit Suisse Group reissued an “underperform” rating and set a $28.00 price target (down from $49.00) on shares of Portola Pharmaceuticals in a research note on Friday, August 10th.

In other Portola Pharmaceuticals news, CEO William Lis sold 5,113 shares of Portola Pharmaceuticals stock in a transaction on Wednesday, June 6th. The stock was sold at an average price of $45.21, for a total transaction of $231,158.73. Following the completion of the sale, the chief executive officer now directly owns 222,035 shares of the company’s stock, valued at approximately $10,038,202.35. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.60% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Portola Pharmaceuticals in the 1st quarter valued at $128,000. Silvant Capital Management LLC purchased a new position in shares of Portola Pharmaceuticals in the 1st quarter valued at $186,000. SeaCrest Wealth Management LLC purchased a new position in shares of Portola Pharmaceuticals in the 2nd quarter valued at $191,000. BB&T Securities LLC purchased a new position in shares of Portola Pharmaceuticals in the 2nd quarter valued at $201,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in shares of Portola Pharmaceuticals in the 2nd quarter valued at $230,000. Institutional investors and hedge funds own 87.09% of the company’s stock.

Shares of NASDAQ:PTLA traded down $0.33 during trading on Wednesday, hitting $25.26. The company had a trading volume of 9,467 shares, compared to its average volume of 1,330,874. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -5.32 and a beta of 1.76. Portola Pharmaceuticals has a one year low of $24.63 and a one year high of $64.56. The company has a debt-to-equity ratio of 0.91, a current ratio of 6.69 and a quick ratio of 6.59.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.12). The company had revenue of $4.01 million during the quarter, compared to the consensus estimate of $6.35 million. Portola Pharmaceuticals had a negative net margin of 1,503.29% and a negative return on equity of 111.64%. Portola Pharmaceuticals’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned ($1.22) earnings per share. analysts expect that Portola Pharmaceuticals will post -5.33 earnings per share for the current fiscal year.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.